XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Recognition and Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 100,806 $ 78,946 $ 186,324 $ 157,624
Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 100,806 68,946 186,324 147,624
Revenue from collaborative arrangements with a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 0 10,000 0 10,000
GSK        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 100,806 78,946 186,324 157,624
GSK | Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 104,262 72,402 193,236 154,536
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (6,912) (6,912)
Total net revenue 100,806 68,946 186,324 147,624
GSK | RELVAR/BREO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 65,916 45,570 122,306 101,719
GSK | ANORO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 11,960 11,199 22,460 21,049
GSK | TRELEGY        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 26,386 15,633 48,470 31,768
GSK | Revenue from collaborative arrangements with a related party | Strategic alliance - MABA program        
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 0 $ 10,000 $ 0 $ 10,000